Producer
Sartorius AG
German life sciences company that manufactured the world's first industrial nitrocellulose membrane in 1960 in Göttingen. Its Unisart® CN series is one of the two dominant global LFA membrane brands. Key OEM supplier to virtually every major rapid test manufacturer.
3
Inputs supplied
3
Goods downstream
1
Facilities
0
Stories
What they make
3 inputs Sartorius AG supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Sartorius AG makes, pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map, where this supply-chain role fits within their broader business.
Bioprocess Solutions (Single-Use Bioreactors & Filtration)
58%Nitrocellulose Membranes (Lateral Flow Assay)
12%Lab Products & Precision Instruments
30%
Intelligence
What's known
Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.
Did you know2023
Sartorius AG — best known among chemists and biologists for its precision laboratory balances (the 'Sartorius balance' is the iconic analytical scale on every lab bench) — is also the dominant global supplier of single-use Cellbag bioreactor bags for biologics manufacturing AND one of only 2-3 global producers of the nitrocellulose membrane inside every rapid diagnostic test. The precision balance that weighs your drug compound to 0.01 mg, the plastic bag that grew the cells that made your COVID vaccine, and the nitrocellulose strip in your COVID rapid test are all manufactured by the same 1870-founded German company in Göttingen. Lab instruments, vaccine manufacturing consumables, and diagnostic substrates are three completely separate supply chains — but they all converge at Sartorius. During 2020-2021, Sartorius was simultaneously supply-constrained in NC membranes (rapid test rationing) and supply-ramp for bioreactor bags (vaccine manufacturing) — the same facility was a chokepoint for both disease testing and disease treatment.
Sartorius AG ↗Origin2022
Sartorius AG — now primarily known as a biopharma bioprocessing equipment company — manufactured the world's first industrial-scale nitrocellulose membrane in 1960 in Göttingen, Germany. All Unisart® lateral flow membranes are still made at this same Göttingen campus. Every rapid antigen test using a Sartorius membrane traces its critical component to a single German city — a geographic chokepoint predating COVID-19 by 60 years.
Sartorius AG ↗Capacity2023
Sartorius' revenue trajectory tells the COVID biotech story: €2.3B in 2019, rising to €3.4B (2020), €3.7B (2021), €4.4B (2022 peak) as COVID vaccine and mRNA therapeutic production drove unprecedented demand for single-use bioreactor bags, TFF cassettes, and sterile filters. Then the collapse: €3.4B (2023), ~€3.2B (2024 estimate) as biopharma customers destocked COVID-era inventory. Sartorius' stock fell from a peak of ~€600 (early 2022) to ~€250 (late 2023) — a destruction of €20B+ market cap in 18 months. The underlying demand for biologics manufacturing equipment is structurally growing (mRNA pipeline, CAR-T, bispecific antibodies) but the post-COVID inventory correction temporarily obscured this. Sartorius' experience shows how a critical industrial infrastructure company can become a victim of its own strategic importance.
Sartorius AG ↗